Introduction
============

Colorectal cancer (CRC) is the fourth most common cancer in men and third most common cancer in women worldwide \[[@B1]\]. Although patients diagnosed with early stage disease have a high cure rate, many present later when five year survival is 5-8%. Palliative chemotherapy is the only option for the majority of these patients. With advances in systemic chemotherapy for metastatic CRC, survival has increased from 12 months with fluorouracil (5-FU) monotherapy to about 2 years with the addition of oxaliplatin, irinotecan, and targeted or biologic agents \[[@B2]-[@B4]\].

The epithelial growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) are related to the growth, survival, proliferation and metastasis of tumor cells. Thus, targeted agents that are capable of inhibiting signal transduction through EGFR and VEGF have been developed \[[@B5]-[@B8]\]. This led to the advent of many EGFR- and VEGF-inhibitors, of which cetuximab and bevacizumab are among the most common. Cetuximab efficacy for front line chemotherapy improves when administered with anti-EGFR agents, but this effect is restricted to patients with wild type Kirsten-ras (*KRAS*) gene \[[@B9],[@B10]\]. Therefore, current guidelines recommend testing the status of *KRAS* mutation as a routine procedure to avoid unnecessary treatment potentially associated with significant toxicity. This patient selection engenders significant cost savings in health care systems \[[@B11]\]. Bevacizumab is humanized monoclonal antibody against VEGF, the major mediator of angiogenesis. Bevacizumab is the first drug developed as an inhibitor of angiogenesis to be approved by the Food and Drug Administration (FDA), based on the survival benefit seen in a landmark trial for first-line treatment of metastatic CRC when combined with conventional chemotherapy \[[@B12]\]. However, unlike cetuximab, despite intense research efforts, no biomarker that can identify the patients who would benefit from bevacizumab therapy has yet been found. The cost and toxicity of bevacizumab accentuate the need for predictive markers for both efficacy and toxicity.

VEGF is an important regulator of physiologic and pathologic angiogenesis and is overexpressed in many malignancies \[[@B13]\]. VEGF and EGFR pathways interact, increasing angiogenesis \[[@B14],[@B15]\]. RAS pathway signaling increases expression of VEGF and represses negative regulators of angiogenesis, suggesting that aberrations in *KRAS* may influence the response to anti-angiogenic therapy \[[@B16]-[@B18]\]. However, the role of *KRAS* mutation as a biomarker for anti-VEGF remains controversial.

We evaluated the role for the status of *KRAS* mutation as predictive and prognostic marker in CRC with anti-VEGF therapy.

Materials and Methods
=====================

1. Patients
-----------

We reviewed the records of 32 CRC patients who were available for *KRAS* mutation status and treated with cytotoxic chemotherapy plus bevacizumab as a first-line therapy at the Korea University Anam Hospital, Seoul, Korea between April 2007 and January 2011. All patients had pathologically or cytologically proven metastatic or recurrent CRC. During treatment, all patients received bevacizumab and some patients with wild type *KRAS* were treated by anti-EGFR therapies. Clinical information collected from the medical records of each patient were physical examination, surgical and pathologic reports, and imaging. Medical information including chemotherapy regimens, response, the date of progression, date of last visit and deaths were collected.

2. Treatment
------------

The decision whether chemotherapy was conducted or not depended, in all cases, on the discussion between physician and patient. The chemotherapy regimen was determined by the physician. All three chemotherapeutic agents (5-FU, oxaliplatin, and irinotecan) were used over the treatment course. Bevacizumab was always administered concomitantly with intravenous or oral 5-FU plus oxaliplatin (FOLFOX or XELOX) regimen for the first-line treatment. Some patients with wild type *KRAS* were treated by an anti-EGFR agent, but not combined with bevacizumab. All tumors were evaluated after every three or four cycles of chemotherapy, by computed tomography scan and other tests that were used initially to stage the tumor. Responses were classified according to the Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.0.

3. Mutation analysis
--------------------

We extracted DNA from five paraffin sections of 10 µm thickness containing a representative portion of tumor tissue (Qiagen, Hilden, Germany). Fifty nanograms of DNA were amplified in a 20 µL reaction solution containing 10 µL of 2×concentrated Hot StarTaq Master Mix (Qiagen), including polymerase chain reaction buffer, 3 mM MgCl~2~, 400 µM each of dNTP, and 0.3 µM each of the primer pairs (codon 12, 13; F: 5\'-CGTCTGCAGTCAACTGGAAT, R: 5\'-GAGAATGGTCCTGCACCAGTAA). Amplifications were performed using a 15 minute initial denaturation at 95℃, followed by 35 cycles of 30 seconds at 94℃, 30 seconds at 59℃, 30 seconds at 72℃, and a 10 minute final extension at 72℃. The polymerase chain reaction (PCR) products were then 2% gel-purified using the QIAgen gel extraction kit (Qiagen).

DNA sequencing was conducted as follows. First, digested mutated DNA was used as a template for the second PCR, in which the primer Ras 3 antisense; (5\'-GGATGGTCCTCCACCAGTAATATGGATATTA-3\') was used instead of Ras 2 (3\'). The PCR was run under the same conditions as the first PCR for 32 cycles. Because of the nested antisense primer (Ras 3), the second PCR generated a fragment of 152 bp. This mutated DNA was excised from 3% agarose gels. The amplicons were then purified using the High Pure PCR Product Purification kit (Boehringer-Mannheim, Mannheim, Germany). Five ng of the purified amplicons was used for sequencing, performed with the Big Dye RR Terminator reaction (ABI, Weiterstadt, Germany). The product was run on a 5% polyacrylamide gel in an ABI 373A Sequencer (ABI) and analyzed for point mutations of the respective a mplicons.

4. Statistical analysis
-----------------------

Treatment outcomes were estimated as response rate (RR), progression free survival (PFS), and overall survival (OS). Tumor response was determined according to RECIST ver. 1.0. PFS was defined as the time from the date of the diagnosis for recurrence or metastatic disease to the date of disease progression or death from any cause. OS was defined as the time between the date of the diagnosis for recurrence or metastatic disease and the date of death. The PFS for oxaliplatin-and irinotecan-based chemotherapy and the OS according to *KRAS* status were analyzed with the Kaplan-Meier method to estimate the probability of survival and survival difference with the log-rank test. The χ^2^-test or Fisher\'s exact test as appropriate compared categorical variables. Two-sided null hypotheses of no difference were rejected if p-values were less than 0.05, or, equivalently, if the 95% confidence interals (CIs) of risk point estimates excluded 1.

Cox proportional hazards regression model was employed in univariate and multivariate analyses to identify the significant independent prognostic factors of various clinical parameters for survival. Variables found significant at the 0.05 level in univariate analysis for OS were included in multivariate analysis.

Results
=======

1. Patient characteristics
--------------------------

Thirty two patients who were diagnosed with metastatic or recurrent CRC between April 2007 and January 2011 were tested for *KRAS* mutation status and received oxaliplatin based chemotherapy plus bevacizumab as first-line therapy. Among 32 patients who experienced disease progression after starting first-line therapy, 28 (87.5%) were treated with irinotecan based chemotherapy. During treatment, six of 32 patients received anti-EGFR therapies, not combined with bevacizumab. *KRAS* mutations were detected in 59.3% of tested patients. [Table 1](#T1){ref-type="table"} summarizes the patient characteristics by *KRAS* mutational status. The median age was 53.5 years (range, 20 to 70 years) at diagnosis, and the male/female ratio was 2.5/1.0. Patient characteristics were similar between the *KRAS* mutation and the *KRAS* wild type groups. Moderate/poor differentiated tumors were observed more frequently in those with *KRAS* wild type compared to *KRAS* mutant patients (p=0.05).

2. Outcomes for chemotherapy
----------------------------

The overall RR of bevacizumab plus FOLFOX or XELOX was 50.0% and disease control rates 84.3% ([Table 2](#T2){ref-type="table"}). There was no significant difference for response (p=0.72) according to the status of *KRAS* mutation. Median PFS for first-line chemotherapy was 7.1 (95% CI, 5.8 to 8.4). There was no significant difference for PFS between *KRAS* mutation group and wild group (6.3 months; 95% CI, 3.2 to 9.4) vs. 8.5 months (95% CI, 4.5 to 12.4; p=0.98) ([Fig. 1](#F1){ref-type="fig"}). In the second-line therapy, the overall RR was 25% and disease control rates 67.8%. According to the status of *KRAS* mutation, there was no significant difference of RR ([Table 2](#T2){ref-type="table"}). Moreover, patients with *KRAS* mutation showed similar OS as compared to patients without mutation ([Fig. 2](#F2){ref-type="fig"}).

3. Prognostic analysis
----------------------

Results of prognostic analysis are provided in [Table 3](#T3){ref-type="table"}. When *KRAS* was assessed as a prognostic marker, there was no evidence as an independent factor for PFS to bevacizumab plus FOLFOX or XELOX in univariate analysis (hazard ratio, 1.007; 95% CI, 0.469 to 2.162; p=0.986). Similarly, there was no evidence that *KRAS* mutation was an independent prognostic factor for OS (hazard ratio, 0.548; 95% CI, 0.226 to 1.328; p=0.183). In univariate analysis of OS, the number of metastasizes was only statistically significant prognostic factor. In addition, anti-EGFR therapies did not influence OS.

Discussion
==========

For metastatic CRC, bevacizumab is clinically beneficial in combination with 5-FU alone or 5-FU combined with either oxaliplatin or irinotecan. However, no well-validated biomarkers have emerged to include or exclude patients from bevacizumab. It is unknown whether interactions in host-tumor microenvironment, biological features unique to the tumor, or features unique to the patients are most likely to yield predictors of therapy responsiveness \[[@B19]\].

Clinical and preclinical research indicate that alterations in the Ras/Raf/Mek/Erk pathway may have clinical relevance to the efficacy of anti-VEGF therapies \[[@B16]-[@B18],[@B20]\]. In our study, there was no significant difference in response (p=0.72) or PFS (p=0.98) with the addition of bevacizumab to first-line chemotherapy by *KRAS* mutation status. This is consistent with previous retrospective studies. In the Hurwits study, there was no apparent interaction on the improvement PFS for *KRAS* status when bevacizumab was given in addition to irinotecan plus FU (IFL) chemotherapy \[[@B12]\]. However, there was a difference in RR with the addition of bevacizumab to IFL by *KRAS* mutation status. These findings were recently confirmed in the Australasian Gastrointestinal Trials Group Mitomycin Avastin Xeloda (AGITG MAX) study \[[@B21]\]. The MAX study reported that *KRAS* gene mutation status was neither prognostic for OS nor predictive of bevacizumab outcome in patients with advanced CRC. The relation between RR and *KRAS* mutation in MAX study was similar to that of the Hurwits study \[[@B12],[@B21]\]. Although the Hurwitz study and MAX trial evaluated the role of *KRAS* mutation as predictive marker for the addition of bevacizumab to first-line chemotherapy, chemotherapy-backbones used in these studies were not suitable in metastatic CRC patients with relatively good performance status. There is no conclusive evidence that bevacizumab has superior activity when combined with specific chemotherapy, and rates of serious adverse events are similar for patients receiving FOLFOX, FOLFIRI, or XELOX. Thus all of these chemotherapy backbones may appropriate for combination with bevacizumab in the first-line treatment setting. In our study, all patients received bevacizumab plus FOLFOX as first-line therapy. Thus, our data set of patients receiving standard cytotoxic chemotherapy plus bevacizumab adds significant evidence to the lack of influence of *KRAS* status on the outcome of bevacizumab.

The prognostic values of *KRAS* mutation remain controversial in CRC. Our results indicate that *KRAS* mutation status has no major prognostic value for OS in patients with metastatic CRC with systemic therapy including bevacizumab. This finding was in accord with previous studies. The CO.17 study analyzed the prognostic impact by assessing the relation between *KRAS* status and survival in patients with best supportive care alone \[[@B10]\]. No significant difference was evident in median OS in patients with *KRAS* wild type or other mutations. Also, Reinacher-Schick et al. \[[@B22]\]. reported no evidence of *KRAS* gene status having prognostic value in metastatic CRC with bevacizumab containing therapy. In the MAX trial, *KRAS* gene mutation status was neither prognostic for PFS or OS in patients with advanced CRC \[[@B21]\]. However, conflicting findings were reported simultaneously in the two large collaborative Kristen Ras in Colorectal Cancer Collaborative Group (RASCAL) studies of 2,721 and 4,268 patients with CRC, respectively \[[@B23]\]. While the first RASCAL study showed an increased risk of recurrence and death linked to *KRAS* mutation, the second refined this observation to report significant prognostic value in failure free survival only with the G12V mutation in Duke\'s C patients. Thus, the clinical impact of our results is difficult to predict because many other factors might affect our finding. Furthermore, the subanalysis from the Hurwitz study showed that patients with *KRAS* gene mutation had a lower overall PFS and OS \[[@B12]\].

Our study was a retrospective analysis with small sample size. Also, the prognosis of CRC was affected by mutational status of many other genes as well as *KRAS*. The tumorigenesis and tumor progression of CRC result from multiple genetic and epigenetic abnormalities, including defective DNA mismatch repair and mutation of *KRAS*, *NRAS*, *BRAF*, *PI3K*, *PIK3CA*, and p5 \[[@B24],[@B25]\]. These genetic and epigenetic changes may affect the survival of patients with CRC, although in this study we focused only the status of *KRAS* mutation to analyze the survival of CRC.

The use of bevacizumab in metastatic CRC has been a topic of much debate. Current research is not in agreement. Moreover, cost-effectiveness is unclear. These problems may be caused by the lack of a confirmative marker for the benefit of bevacizumab. Based on many studies including this one, the clinical benefit from bevacizumab appears to be independent of *KRAS* status. Nevertheless, researchers must make efforts to excavate predictive or prognostic biomarkers for biologic agents including bevacizumab. These efforts make us move closer to truly personalized medicine of cancer, ensuring maximum effectiveness with minimal toxicities and a minimum effect on resources.

Conclusion
==========

VEGF is an important regulator of physiologic and pathologic angiogenesis and is overexpressed in many malignancies. VEGF and EGFR pathways interact, increasing angiogenesis. RAS pathway signaling increases expression of VEGF and represses negative regulators of angiogenesis, suggesting that aberrations in *KRAS* influence the response to anti-angiogenic therapy. However, the role of *KRAS* mutation as a biomarker for anti-VEGF remains controversial. Based on our analysis, *KRAS* mutation revealed neither a predictive for bevacizumab nor a prognostic for OS in CRC patients receiving anti-VEGF therapy.
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MT, mutant; WT, wild type; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.
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VEGF, vascular endothelial growth factor; WT, wild type; MT, mutant.
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CRC, colorectal cancer; VEGF, vascular endothelial growth factor; CI, confidence interval; PFS, progression free survival; EGFR, epidermal growth factor receptor.
